

Candesartan Cilexetil

【OBLO】 Blopress® 8mg/Tab

ATC Code : C09CA06

中文名： 博脈舒錠 «台灣武田»

適應症： 1.本態性高血壓。

2.治療左心室射出率 $\leq 40\%$ 之心臟衰竭病患，作為血管加壓素轉化酶抑制劑（ACE-inhibitors）輔助療法，或使用於無法耐受血管加壓素轉化酶抑制劑（ACE-inhibitors）的病人，以減少心臟血管死亡率或心衰竭導致之住院。

藥理分類： Angiotensin II Receptor Blocker; Antihypertensive.

用法用量： **Administration:** orally, administer with or without food.

Indications and dosage regimens:

Hypertension, Alone or in combination with other antihypertensive agents:

— Initially, 16 mg once daily or in 2 divided doses.

Adjust dosage at approximately monthly intervals to achieve BP control.

— Usual dosage:

8-32 mg daily, given in 1 dose or 2 divided doses; no additional therapeutic benefit with higher dosages.

— Moderate to severe hepatic or renal impairment:

4 or 8 mg daily.

Heart failure, (NYHA class II to IV, ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations:

Initial, 4 mg once daily, double dose at approximately 2- week intervals, as tolerated; target dose 32 mg daily.

不良反應： 背痛、暈眩、頭痛、噁心、高血鉀、上呼吸道感染。

交互作用：

1. **Aliskiren:** ↑ risk of hyperkalemia, renal impairment, and hypotension.
2. **ACEIs:** ↑ risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
3. **Digoxin:** ↑ risk of digoxin toxicity (nausea, vomiting, arrhythmias).
4. **Cellcept®:** ↓ mycophenolate exposure and possible reduced efficacy.
5. **Lithium:** ↑ risk of lithium toxicity.
6. **Trimethoprim, potassium citrate:** ↑ risk of hyperkalemia.

注意事項： 1.飯前或飯後服用均可。

2.若有經常咳嗽，應告知醫師。

3.孕婦使用前請先諮詢醫師。

4.嚴重肝功能不全或膽汁鬱滯者禁用。

懷 孕 期： 1.不建議使用於初期妊娠。禁用於懷孕第二期及第三期。

2. **[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue as soon as possible.**

授 乳 期： 1.由於缺乏哺乳期間使用 Blopress®的資訊，故哺乳時不建議使用 Blopress®，尤其是為新生兒或早產兒哺乳期間。

2. Candesartan is present in breast milk.

3. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother.